Suggested Topics within your search.
Showing 341 - 360 results of 2,144 for search '"immune response"', query time: 0.11s Refine Results
  1. 341
  2. 342

    Hsa_circ_0000479/Hsa-miR-149-5p/RIG-I, IL-6 Axis: A Potential Novel Pathway to Regulate Immune Response against COVID-19 by Zahra Firoozi, Elham Mohammadisoleimani, Abbas Shahi, Mohammad Mehdi Naghizadeh, Ebrahim Mirzaei, Ali Ghanbari Asad, Zahra Salmanpour, Seyed Mohamad Javad Nouri, Yaser Mansoori

    Published 2022-01-01
    “…Upregulation of hsa_circ_0000479, RIG-I, and IL-6, and downregulation of hsa-miR-149-5p, along with correlation studies, indicate that hsa_circ_0000479/hsa-miR-149-5p/RIG-I, IL-6 axis could play a role in regulating the immune response against SARS-CoV-2. However, more studies are needed in this area.…”
    Get full text
    Article
  3. 343
  4. 344
  5. 345
  6. 346
  7. 347
  8. 348
  9. 349
  10. 350
  11. 351
  12. 352
  13. 353

    The probable progression of Epstein-Barr virus (EBV) to chronic active EBV/reactivation weakens the immune response and stimulates Cryptococcus neoformans infection, which invariably proves fatal: a case report and review of the literature by Gargee Mishra, Gaurav Sarnaik, Joydeep Samanta, Archana Keche, Sanjay Singh Negi

    Published 2025-01-01
    “…We have reported here the fatal outcome of Epstein-Barr virus (EBV) infection in a 58-year-old male who had probably developed reactivation/chronic active EBV (CAEBV) which gave rise to various neurological deficits, pancytopenia, and a lower CD4 count in the patient. The decreased immune response helped Cryptococcus neoformans (C. neoformans) to manifest a disseminated infection. …”
    Get full text
    Article
  14. 354
  15. 355

    A high-valence bismuth(V) nanoplatform triggers cancer cell death and anti-tumor immune responses with exogenous excitation-free endogenous H2O2- and O2-independent ROS generation by Yizhang Tang, Xujiang Yu, Liangrui He, Meng Tang, Wenji Yue, Ruitong Chen, Jie Zhao, Qi Pan, Wanwan Li

    Published 2025-01-01
    “…NaBiVO3-PEG intratumorally administered initiates robust therapeutic efficacies against both primary and distant tumors and activates systemic immune responses to combat tumor metastasis. NaBiVO3-PEG intravenously administered can efficiently accumulate at the tumor site for further real-time computed tomography monitoring, immunotherapy, or alternative synergistic immune-radiotherapy. …”
    Get full text
    Article
  16. 356
  17. 357
  18. 358
  19. 359
  20. 360